pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·May 5·1 min read
save

Pfizer's Albert Bourla says he has no mega-merger plans

The most candid man in pharma strikes again. When asked on Tuesday’s earnings call whether Pfizer would consider a “transformative M&A” deal in the near or medium term, CEO Albert Bourla said it wouldn’t. “We ...

May 5, 2026·read at Endpoints ↗

Albert Bourla, Pfizer CEO (Michael Nagle/Bloomberg via Getty Images) May 5, 2026 02:16 PM EDT DealsR&DPharma Pfiz­er's Al­bert Bourla on mega-merg­er prospects: 'No' Max Bayer Senior Reporter The most can­did man in phar­ma strikes again. When asked on Tues­day’s earn­ings call whether Pfiz­er would con­sid­er a “trans­for­ma­tive M&A” deal in the near … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

source

Reporting by Endpoints.

read at Endpoints ↗
87 words · retrieved May 5
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
PFIZER3

related stories

  • May 6Neoadjuvant T-DXd Followed by THP Improves RCB in HER2+ Breast Canceronclive
  • May 6CellCentric raises $220M for a ‘transformative’ multiple myeloma medicineBioPharma Dive
  • May 5Pfizer ends Trillium-related development as R&D spend jumpsEndpoints
  • May 5STAT+: Are analysts too quick to gloss over Lilly’s liver case?STAT
  • May 4UCB to acquire maker of antibody treatments for autoimmune diseasesSTAT